General Information of Drug (ID: DM7IK68)

Drug Name
MRS 2219 Drug Info
Synonyms MRS2219; MRS-2220
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3960826
CAS Number
CAS 14141-47-0
TTD Drug ID
DM7IK68

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug(s) Targeting P2X purinoceptor 1 (P2RX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BzATP DM37GYA Discovery agent N.A. Investigative [3]
L-betagamma-meATP DMTNQCE Discovery agent N.A. Investigative [3]
TNP-ATP DMVZY0X Discovery agent N.A. Investigative [4]
NF023 DMJ4GO9 Discovery agent N.A. Investigative [3]
NF449 DM816Z2 Discovery agent N.A. Investigative [5]
Ip5I DMB2YXN Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2X purinoceptor 1 (P2RX1) TTJW7B3 P2RX1_HUMAN Modulator (allosteric modulator) [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6496).
2 A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
4 Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
5 Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57.